GEORGE P. CANELLOS, M.D., F.A.C.P.; VINCENT T. DeVITA, M.D., F.A.C.P.; G. LENNARD GOLD, M.D., F.A.C.P.; BRUCE A. CHABNER, M.D., F.A.C.P.; PHILIP S. SCHEIN, M.D., F.A.C.P.; ROBERT C. YOUNG, M.D., F.A.C.P.
CANELLOS GP, DeVITA VT, GOLD GL, CHABNER BA, SCHEIN PS, YOUNG RC. Combination Chemotherapy for Advanced Breast Cancer: Response and Effect on Survival. Ann Intern Med. 1976;84:389-392. doi: 10.7326/0003-4819-84-4-389
Download citation file:
Published: Ann Intern Med. 1976;84(4):389-392.
Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF (P), which included methotrexate, 60 mg/m2, and 5-fluorouracil, 700 mg/m2, intravenously on the first and eighth days, in addition to cyclophosphamide, 100 mg/m2, and prednisone, 40 mg/m2, by mouth daily from the first to the fourteenth day of a 28-day cycle. Only 2 of 25 patients responded to hormonal therapy or endocrine ablation. Twenty-seven of the 40 patients (68%) had a complete response (8 patients) or partial response (19 patients). Lung, soft tissue, and nodal metastases were the most responsive sites. The median duration of antitumor response was 8 months, with a median survival of 18 months for the responding group. The nonresponders had a median survival of 4 months. The toxicity was primarily hematologic and was especially severe in patients with functional liver impairment due to metastatic disease.
Learn more about subscription options.
Register Now for a free account.
Breast Cancer, Hematology/Oncology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only